Literature DB >> 18500246

Telomere dysfunction and tumour suppression: the senescence connection.

Yibin Deng1, Suzanne S Chan, Sandy Chang.   

Abstract

Long-lived organisms such as humans have evolved several intrinsic tumour suppressor mechanisms to combat the slew of oncogenic somatic mutations that constantly arise in proliferating stem-cell compartments. One of these anticancer barriers is the telomere, a specialized nucleoprotein complex that caps the ends of eukaryotic chromosome. Impaired telomere function activates the canonical DNA damage response pathway that engages p53 to initiate apoptosis or replicative senescence. Here, we discuss how p53-dependent senescence induced by dysfunctional telomeres may be as potent as apoptosis in suppressing tumorigenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500246      PMCID: PMC3688269          DOI: 10.1038/nrc2393

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  98 in total

1.  p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis.

Authors:  L Chin; S E Artandi; Q Shen; A Tam; S L Lee; G J Gottlieb; C W Greider; R A DePinho
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

2.  The Stability of Broken Ends of Chromosomes in Zea Mays.

Authors:  B McClintock
Journal:  Genetics       Date:  1941-03       Impact factor: 4.562

3.  Telomerase activity in human germline and embryonic tissues and cells.

Authors:  W E Wright; M A Piatyszek; W E Rainey; W Byrd; J W Shay
Journal:  Dev Genet       Date:  1996

4.  POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination.

Authors:  Hua He; Asha S Multani; Wilfredo Cosme-Blanco; Hidetoshi Tahara; Jin Ma; Sen Pathak; Yibin Deng; Sandy Chang
Journal:  EMBO J       Date:  2006-10-19       Impact factor: 11.598

5.  Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis.

Authors:  E González-Suárez; E Samper; J M Flores; M A Blasco
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

7.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.

Authors:  Julien Sage; Abigail L Miller; Pedro A Pérez-Mancera; Julianne M Wysocki; Tyler Jacks
Journal:  Nature       Date:  2003-07-10       Impact factor: 49.962

8.  Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing.

Authors:  Kwok-Kin Wong; Richard S Maser; Robert M Bachoo; Jayant Menon; Daniel R Carrasco; Yansong Gu; Frederick W Alt; Ronald A DePinho
Journal:  Nature       Date:  2003-01-22       Impact factor: 49.962

Review 9.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  The POT1-TPP1 telomere complex is a telomerase processivity factor.

Authors:  Feng Wang; Elaine R Podell; Arthur J Zaug; Yuting Yang; Paul Baciu; Thomas R Cech; Ming Lei
Journal:  Nature       Date:  2007-01-21       Impact factor: 69.504

View more
  157 in total

1.  Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Han-Qiang Liu; Jia-Ze An; Juan Liu; Ye-Fa Yang; Hong-Xin Zhang; Bin-Yu Zhao; Ji-Bin Li; Hu-Shan Yang; Zhi-Nan Chen; Jin-Liang Xing
Journal:  Carcinogenesis       Date:  2012-02-08       Impact factor: 4.944

2.  Telomere capping in non-dividing yeast cells requires Yku and Rap1.

Authors:  Momchil D Vodenicharov; Nancy Laterreur; Raymund J Wellinger
Journal:  EMBO J       Date:  2010-07-13       Impact factor: 11.598

Review 3.  Cellular Senescence: The Trojan Horse in Chronic Lung Diseases.

Authors:  Shruthi Hamsanathan; Jonathan K Alder; Jacobo Sellares; Mauricio Rojas; Aditi U Gurkar; Ana L Mora
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

4.  CTC1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion.

Authors:  Peili Gu; Jin-Na Min; Yang Wang; Chenhui Huang; Tao Peng; Weihang Chai; Sandy Chang
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

5.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

6.  p16(INK4a) protects against dysfunctional telomere-induced ATR-dependent DNA damage responses.

Authors:  Yang Wang; Norman Sharpless; Sandy Chang
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

7.  miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation.

Authors:  G Yang; Y Gong; Q Wang; L Wang; X Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

8.  WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway.

Authors:  Romuald Binet; Damien Ythier; Ana I Robles; Manuel Collado; Delphine Larrieu; Claire Fonti; Elisabeth Brambilla; Christian Brambilla; Manuel Serrano; Curtis C Harris; Rémy Pedeux
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

9.  Characterization of a K+-induced conformational switch in a human telomeric DNA oligonucleotide using 2-aminopurine fluorescence.

Authors:  Robert D Gray; Luigi Petraccone; John O Trent; Jonathan B Chaires
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

10.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component.

Authors:  Craig Nicholls; Alexander Ruvantha Pinto; He Li; Ling Li; Lihui Wang; Richard Simpson; Jun-Ping Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.